Lenalidomide maintenance prolonged PFS among elderly patients with diffuse large B-cell lymphoma who had achieved partial or complete response to standard therapy (RCHOP), according to results of the phase 3 REMARC trial. It did not translate into OS advantage in the experimental arm. I would discus...